Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII

Thrombosis and Haemostasis

Volumn 76, Issue 2, 1996, Pages 171-176

  Bröijersén, Anders ^a,b   Hamsten, Anders ^b   Silveira, Angela ^b   Fatah, Kamaran ^a   Goodall, Alison H ^c   Eriksson, Mats ^b   Angelin, Bo ^b   Hjemdahl, Paul ^a  

^a Department of Clinical Pharmacology ^*

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTITHROMBIN; APOLIPOPROTEIN; BLOOD CLOTTING FACTOR 7; FIBRINOGEN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; NORADRENALIN; PROTHROMBIN; THROMBIN; TRIACYLGLYCEROL;

ADRENALIN BLOOD LEVEL; ADULT; AGED; ARTICLE; CHEMICAL STRUCTURE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; FIBRINOGEN BLOOD LEVEL; HEART RATE; HUMAN; HYPERLIPIDEMIA; MALE; MENTAL STRESS; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; REST; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0029841822     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650548     Document Type: Article

References (43)

1. Salomaa V, Rasi V, Pekkanen J, Jauhiainen M, Vahtera E, Pietinen P, Korhonen H, Kuulasmaa K, Ehnholm C. The effects of saturated fat and n-6 polyunsaturated fat on postprandial lipemia and hemostatic activity. Atherosclerosis 1993; 103: 1-11.
2. Silveira A, Karpe F, Blombäck M, Steiner G, Walldius G, Hamsten A. Activation of coagulation factor VII during alimentary lipemia. Arterioscler Thromb 1994; 14: 60-9.
3. Scarabin PY, Bara L, Samama M, Orssaud G. Further evidence that activated factor VII is related to plasma lipids. Br J Haematol 1985; 61: 186-7.
4. Moor E, Silveira A, van't Hooft F, Suontaka A-M, Eriksson P, Blombäck M, Hamsten A. Coagulation factor VII mass and activity in young men with myocardial infarction at a young age: role of plasma lipoproteins and factor VII genotype. Arterioscler Thromb Vase Biol 1995; 15: 655-64.
5. Miller GJ, Walter SJ, Stirling Y, Thompson SG, Esnouf MP, Meade TW. Assay of factor VII activity by two techniques: evidence for increased conversion of VII to VIIa in hyperlipidaemia, with possible implications for ischaemic heart disease. Br J Haematol 1985; 59: 249-58.
6. Folsom AR, Wu KK, Davis CE, Conlan MG, Solie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991; 91: 191-205.
7. Lowe GDO, Drummond MM, Third JLHC, Brenner WF, Forbes CD, Prentice CR, Lawrie TD. Increased plasma fibrinogen and platelet-aggregates in type II hyperlipoproteinaemia. Thromb Haemost 1980; 42: 1503-7.
8. Manninen V, Malkonen M, Eisalo A, Virtamo J, Tuomilehto J, Kuusisto P. Gemfibrozil in the treatment of dyslipidemia. A five-year follow-up study. Acta Med Scand 1982; 668 (suppl): 82-7.
9. Weintraub MS, Eisenberg S, Breslow JL. Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil. J Clin Invest 1987; 79: 1110-9.
10. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Mäenpää M, Mälkönen M, Mänttari M, Norda S, Pasternach A, Pilikarainen J, Romo M, Sjöblom T, Nikkilä EA. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-45.
11. Andersen P, Smith P, Seljeflot I, Brataker S, Arnesen H. Effects of gemfibrozil on lipids and haemostasis after myocardial infarction. Thromb Haemost 1990; 63: 174-7.
12. Stringer MD, Steadman CA, Kakkar VV. Gemfibrozil in hyperlipidaemic patients with peripheral arterial disease: some undiscovered actions. Curr Med Res Opin 1990; 12: 207-14.
13. Avellone G, Di Garbo V, Cordova R, Piliego T, Raneli G, De Simone R, Bompiani GD. Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia. Blood Coag Fibrinol 1995; 6: 543-8.
14. l+2 concentration, a marker of coagulability, in patients with coronary heart disease. Thromb Haemost 1992; 67: 503-6.
15. Branchi A, Rovellini A, Sommariva D, Gugliandolo AG, Fasoli A. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thromb Haemost 1993; 70: 241-3.
16. O'Brien JR, Etherington MD, Shuttleworth RD, Adams CM, Middleton JE, Goodland FC. A pilot study of the effect of gemfibrozil on some haematological parameters. Res Clin Forums 1982; 4: 71-6.
17. Avellone G, di Garbo V, Panno AV, Cordova R, Lepore R, Strano A. Changes induced by gemfibrozil on lipidic, coagulative and fibrinolytic pattern in patients with type IV hyperlipoproteinemia. Int Angiol 1988; 7: 270-7.
18. Mann KG. Factor VII assays, plasma triglyceride levels, and cardiovascular disease risk. Arteriosclerosis 1989; 9: 783-4.
19. Bröijersén A, Eriksson M, Angelin B, Hjelmdahl P. Gemfibrozil enhances platelet activity in patients with combined hyperlipoproteinemia. Arterioscler Thromb Vasc Biol 1995; 15: 121-7.
20. Bröijersén A, Eriksson M, Wiman B, Angelin B, Hjelmdahl P. Gemfibrozil treatment of combined hyperlipoproteinemia: no improvement of fibrinolysis despite marked reduction of plasma triglycerides. Arterioscler Thromb Vase Biol 1996; 16: 511-6.
21. Frankenhaeuser M, Mellis I, Rissler A, Björkvall C, Patkai P. Catecholamine excretion as related to cognitive and emotional reaction patterns. Psychosom Med 1968; 30: 109-20.
22. Vermylen C, de Vreker R, Vetstraete M. A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT test). Clin Chim Acta 1963; 8: 418-24.
23. Wildgoose P, Nemerson Y, Lyng Hansen L, Nielsen FE, Glazer S, Hedner U. Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood 1992; 80: 25-8.
24. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-44.
25. Silveira A, Green F, Karpe F, Blombäck M, Humphries S, Hamsten A. Elevated levels of factor VII activity in the postprandial state: effect of the factor VII Arg-Gln polymorphism. Thromb Haemost 1994; 72: 734-9
26. Blombäck B, Carlsson K, Hessel B, Liljeborg A, Procyk R, Åslund N. Native fibrin gel networks observed by 3 D microscopy, permeation and turbidity. Biochim Biophys Acta 1989; 997: 96-110.
27. Fatah K, Hamsten A, Blombäck B, Blombäck M. Native fibrin gel network properties and coronary heart disease: relations to plasma fibrinogen, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992; 68: 130-5.
28. Blombäck B, Carlsson K, Fatah K, Hessel B, Procyk R. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75: 521-38.
29. Blombäck B, Okada M. Fibrin gel structure and clotting time. Thromb Res 1982; 25: 51-70.
30. Blombäck B, Bannerjee D, Carlsson K, Hamsten A, Hessel B, Procyk R, Silveira A, Zacharski L. Native fibrin gel networks and factors influencing their formation in health and disease. In: Liu C Y and Chien S (Eds). Fibrinogen, Thrombosis, Coagulation, and Fibrinolysis. Plenum Press, New York 1991: 1-23.
31. Carlson K. Lipoprotein fractionation. J Clin Pathol 1973; 26 (suppl 5): 32-7.
32. Lopez-Virella MF, Stone P, Ellis S, Colwell JA. Cholesterol determination in high density lipoproteins separated by three different methods. Clin Chem 1977; 23: 882-4.
33. Hjelmdahl P. Catecholamine measurements in plasma by high-performance liquid chromatography with electrochemical detection. Methods Enzymol 1987; 142: 521-34.
34. Jones B, Kenward MG. Design and analysis of cross-over trials. New York, NY: Chapman and Hall 1989.
35. Bauer KA, Weiss LM, Sparrow D, Vokonas PS, Rosenberg RD. Aging- associated changes in indices of thrombin generation and protein C activation in humans. J Clin Invest 1987; 80: 1527-34.
36. Eichinger S, Wolzt M, Nieszpaur-Los M, Schneider B, Lechner K, Eichler H-G, Kyrie PA. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo. Thromb Haemost 1994; 72: 831-5.
37. Eichinger S, Wolzt M, Schneider B, Nieszpaur-Los M, Heinrichs H, Lechner K, Eichler H-G, Kyrle PA. Effects of recombinant hirudin (r-Hinidin, HBW 023) on coagulation and platelet activation in vivo. Comparison with unfractionated heparin and a low-molecular-weight heparin preparation (Fragmin). Arterioscler Thromb Vasc Biol 1995; 15: 886-92.
38. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD. Persistent activtion of cogulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61-8.
39. Szczeklik A, Dropinski J, Radwan J, Krzanowski M. Persistent generation of thrombin after acute myocardial infarction. Arterioscler Thromb 1992; 12: 548-53.
40. Bauer KA, Kass BL, ten Cate H, Hawiger JJ, Rosenberg RD. Factor IX is activated in vivo by the tissue factor mechanism. Blood 1990; 76: 731-6.
41. Elkeles RS, Chakrabarti R, Vickers M, Stirling Y, Meade TW. Effect of treatment of hyperlipidaemia on haemostatic variables. Br Med J 1980; 281: 973-4.
42. Simpson HCR, Meade TW, Stirling Y, Mann JI, Chakrabarti R, Woolf L. Hypertriglyceridaemia and hypercoagulability. Lancet 1983; i: 786-9.
43. Mitropoulos KA, Reeves BEA, O'Brien DP, Cooper JA, Martin JC. The relationship between factor VII coagulant activity and factor XII activation induced in plasma by endogenous or exogenously added contact surface. Blood Coag Fibrinol 1993; 4: 223-34.